Biodexa Pharmaceuticals Plc ADR (BDRX)

$1.04 -0.03 (-2.80%)
Market Cap 39.10M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 227,100
Avg Vol 1,934,558
Day's Range N/A - N/A
Shares Out 36.54M
Stochastic %K 27%
Beta 1.21
Analysts Strong Sell
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
Love_To_Learn
Love_To_Learn Jun. 16 at 9:37 PM
$BDRX U will be called upon due to soo many factors and reasons and $RFL just so many also $ENVB $DNN !
1 · Reply
DexterTrader
DexterTrader Jun. 16 at 8:08 PM
Looks like people are starting to shift in to ticker ULY now. Huge insider buying going on! Float is so tiny here only 780k shares. once 5$ breaks this could move into 10-15$ range real fast from there… Something is brewing on ticker ULY - could be this weeks top micro float runner! $BNZI $BDRX $CREG $FCEL nice volume spike
0 · Reply
frontiere
frontiere Jun. 16 at 6:31 PM
$BDRX BioDexa ref=$1.04 bought small size as a trading sardine Lindy chart. Ample cash but will need to raise within next 3 quarters.
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:50 AM
$BDRX $RFL $MDAI $AKBA $ICON !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:49 AM
$BDRX $RFL $MDAI $AYTU and side note $KBSX kids
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:49 AM
$BDRX why well for u $RFL n $MDAI recently !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:48 AM
$BDRX $AKBA $RFL $MDAI !!!!!!!!!!!!!!!!
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:48 AM
$BDRX $ICON example 1 !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:48 AM
$BDRX $RFL $MDAI $AKBA ! why i have placed the 2.45 baxk on the board mecahnics again and using multiple stocks to go over it for now such as icon etc. until i take the main source data to it
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:47 AM
$BDRX $RFL $MDAI $AKBA took pandora placed it inside 2.45 wormhole now we r recoding it after its been taken out !
0 · Reply
Latest News on BDRX
Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 5 days ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 12 days ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 17 days ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 25 days ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 25 days ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 5 weeks ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 2 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 2 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 3 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 3 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 3 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 4 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 4 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 4 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 4 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 5 months ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 7 months ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 7 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 8 months ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024, 7:30 AM EDT - 8 months ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Oct 15, 2024, 4:15 PM EDT - 8 months ago

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Oct 4, 2024, 8:30 AM EDT - 9 months ago

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Interim results for the six months ended June 30, 2024

Sep 26, 2024, 8:30 AM EDT - 9 months ago

Interim results for the six months ended June 30, 2024

ADR Ratio Change

Sep 19, 2024, 4:30 PM EDT - 9 months ago

ADR Ratio Change

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Aug 30, 2024, 4:30 PM EDT - 10 months ago

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Jul 23, 2024, 8:30 AM EDT - 11 months ago

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Jul 19, 2024, 8:30 AM EDT - 11 months ago

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why

Jul 11, 2024, 12:44 PM EDT - 1 year ago

Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Jul 11, 2024, 8:30 AM EDT - 1 year ago

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

May 22, 2024, 8:30 AM EDT - 1 year ago

Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises

Love_To_Learn
Love_To_Learn Jun. 16 at 9:37 PM
$BDRX U will be called upon due to soo many factors and reasons and $RFL just so many also $ENVB $DNN !
1 · Reply
DexterTrader
DexterTrader Jun. 16 at 8:08 PM
Looks like people are starting to shift in to ticker ULY now. Huge insider buying going on! Float is so tiny here only 780k shares. once 5$ breaks this could move into 10-15$ range real fast from there… Something is brewing on ticker ULY - could be this weeks top micro float runner! $BNZI $BDRX $CREG $FCEL nice volume spike
0 · Reply
frontiere
frontiere Jun. 16 at 6:31 PM
$BDRX BioDexa ref=$1.04 bought small size as a trading sardine Lindy chart. Ample cash but will need to raise within next 3 quarters.
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:50 AM
$BDRX $RFL $MDAI $AKBA $ICON !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:49 AM
$BDRX $RFL $MDAI $AYTU and side note $KBSX kids
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:49 AM
$BDRX why well for u $RFL n $MDAI recently !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:48 AM
$BDRX $AKBA $RFL $MDAI !!!!!!!!!!!!!!!!
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:48 AM
$BDRX $ICON example 1 !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:48 AM
$BDRX $RFL $MDAI $AKBA ! why i have placed the 2.45 baxk on the board mecahnics again and using multiple stocks to go over it for now such as icon etc. until i take the main source data to it
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:47 AM
$BDRX $RFL $MDAI $AKBA took pandora placed it inside 2.45 wormhole now we r recoding it after its been taken out !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:46 AM
$BDRX $RFL $AKBA notice the 2.35 message recently on RFL and $MDAI !from this !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:46 AM
$BDRX $AKBA $RFL BDRX was suppose to crash sub 1 that day but next message
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:46 AM
$BDRX $AKBA $RFL !
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:45 AM
$BDRX $AKBA APRIL 11th after hours all documented live!
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 11:07 AM
$AKBA $BDRX this is due to pandora was placed inside then and now pandora is out again haif of it days ago to bring order to the changes made market wise
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 13 at 10:48 AM
$BDRX will need u shortly as discussed as the markets are going through a transition and along with crypto my beud. U will be called upon to finish few sequence patterns for markets after $RFLDID its thing and $SBET deliberate tank job
0 · Reply
SmallCapSwinger
SmallCapSwinger Jun. 12 at 6:36 AM
$BDRX I’m at $1.13. I’ll add any drop above $1. Looking for $2.50+. Approaching 52wk low, small float recently announced phase 2 study of Tolimidone in TYPE 1 diabetes , recently announced granting additional $3 million grant from CPRIT to support phase 3 program, recently secured orphan drug designation for eRapa in FAP treatment, has active mixed shelf, so be cautious if she blows.
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 11 at 6:01 PM
$BDRX $SINT $PRPO u will be needed soon to fix some of the chaos $RFL cannot do it alone it and will require the gatekeeper to all crypto to enter its dna and key for markets BEUD!
2 · Reply
The_Gambl3r
The_Gambl3r Jun. 10 at 2:30 PM
$BDRX !
0 · Reply
VolatileGems
VolatileGems Jun. 9 at 3:16 PM
$BDRX watching it at this level
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 6 at 11:00 AM
using $BDRX only with BW related to 1.15* and 2.35 old move for stock coming
0 · Reply
Kommagassar
Kommagassar Jun. 6 at 10:18 AM
$BDRX float 22.02B Yahoo
1 · Reply